CTLA-4 blockade in the treatment of rheumatoid arthritis: an update

References

• McInnes IB, Schett G, The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
   PubMed Web of Science ®Google Scholar
• Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 2010;62:44–52.
   PubMed Web of Science ®Google Scholar
• Middleton J, Americh L, Gayon R, et al. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther. 2004;6:60–72.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J. Biochem. 2015;158:173–179.
   PubMed Web of Science ®Google Scholar
• Straub R, Cutolo M. EULAR textbook on rheumatic diseases. 3rd ed. London, UK: BMJ; 2015. p. 28–68.
   Google Scholar
• Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13:559–575.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459–465.
   PubMed Web of Science ®Google Scholar
• Schiff M, Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clin Rheumatol. 2010;29:583–591.
   PubMed Web of Science ®Google Scholar
• Schiff M, Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50:437–449.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Nadler SG, Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013;12:758–767.
   PubMed Web of Science ®Google Scholar
• Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186:1407–1418.
   PubMed Web of Science ®Google Scholar
• Scarsi M, Ziglioli T, Airò P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010;37:911–916.
   PubMed Web of Science ®Google Scholar
• Rochman Y, Yukawa M, Kartashov AV, et al. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS One. 2015;10(4):e0122198.
   Web of Science ®Google Scholar
• Moret FM1, Bijlsma JW, Lafeber FP, et al. The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines. Arthritis Rheumatol. 2015;67:637–644.
   PubMed Web of Science ®Google Scholar
• Jain M1, Attur M, Furer V, et al. Increased plasma IL-17F levels in rheumatoid arthritis patients are responsive to methotrexate, anti-TNF, and T cell costimulatory modulation. Inflammation. 2015;38:180–186.
   PubMed Web of Science ®Google Scholar
• Gardner DH, Jeffery LE, Soskic B, et al. 1,25(OH)2D3 promotes the efficacy of CD28 costimulation blockade by abatacept. J Immunol. 2015 Aug 14:1500306. [Epub ahead of print].
   Google Scholar
• Kasprowicz DJ, Kohm AP, Berton MT, et al. Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell. J Immunol. 2000;165:680–690.
   PubMed Web of Science ®Google Scholar
• Rau FC, Dieter J, Luo Z, et al. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol. 2009;183:7661–7671.
   PubMed Web of Science ®Google Scholar
• Kanbe K, Chiba J, Nakamura A. Histological evaluation after arthroscopic reconstruction of the shoulder using a polytetrafluoroethylene patch for massive rotator cuff tears. Eur J Orthop Surg Traumatol. 2013;23(Suppl 2):S183–7.
   PubMedGoogle Scholar
• Iwata S1, Nakayamada S, Fukuyo S, et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol. 2015;67:63–73.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Oliveira EM, Anderson DE, et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol. 2001;167:5669–5677.
   PubMed Web of Science ®Google Scholar
• Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41:666–672.
   PubMed Web of Science ®Google Scholar
• Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69:510–516.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71:1815–1819.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Soldano S, Montagna P, et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther. 2009;11:R176.
   PubMed Web of Science ®Google Scholar
• Cutolo M1, Soldano S, Contini P, et al. Intracellular NF-kB-decrease and IKBα increase in human macrophages following CTLA4-Ig treatment. Clin Exp Rheumatol. 2013;3:943–946.
   Google Scholar
• Brizzolara R, Montagna P, Soldano S, et al. Rapid interaction between CTLA-4-Ig (abatacept) and synovial macrophages from patients with rheumatoid arthritis. J Rheumatol. 2013;40:738–740.
   PubMed Web of Science ®Google Scholar
• Axmann R, Herman S, Zaiss M, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008;67:1603–1609.
   PubMed Web of Science ®Google Scholar
• Conaghan PG1, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013;72:1287–1294.
   PubMed Web of Science ®Google Scholar
• Buch MH, Boyle DL, Rosengren S, et al., Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68:1220–1227.
   PubMed Web of Science ®Google Scholar
• Bozec A, Zaiss MM, Kagwiria R, et al., T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. 2014;6:235ra60.
   PubMed Web of Science ®Google Scholar
• Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681–694.
   PubMed Web of Science ®Google Scholar
• Kreisel D, Krupnick AS, Balsara KR, et al., Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol. 2002;169:6154–6161.
   PubMed Web of Science ®Google Scholar
• Lozanoska-Ochser B, Klein NJ, Huang GC, et al. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J Immunol. 2008;181:6109–6116.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Montagna P, Soldano S, et al., CTLA4-Ig/CD86 interactions in cultured human endothelial cells: effects on VEGFR-2 and ICAM1 expression. Clin Exp Rheumatol. 2015;33:250–254.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Kitas GD. The impact of abatacept treatment on the vasculature in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:589.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Wollenhaupt J, Gomez-Reino JJ, et al., Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther. 2015;17:157–164.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Weinblatt ME, Schiff M, et al. Patient-reported outcomes from a 2-year head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Oct 16. DOI:10.1002/acr.22763.
   Google Scholar
• Takahashi N, Kojima T, Kaneko A, et al. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. J Rheumatol. 2015;42:786–793.
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.
   PubMed Web of Science ®Google Scholar
• Salmon JH, Gottenberg JE, Ravaud P, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2015;Jun 5: annrheumdis-2015-207362.
   Google Scholar
• Westhovens R, Kremer JM, Emery P, et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol. 2014;32:553–562.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Paolino S, Pizzorni C, Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol. 2014;32:839–847.
   PubMed Web of Science ®Google Scholar
• Keystone E, Alkhalaf A, Makkawy M. Subcutaneous abatacept in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2015;15:1221–1230.
   PubMed Web of Science ®Google Scholar
• Cutolo M. Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2012;24:312–318.
   PubMed Web of Science ®Google Scholar
• Saalbach A, Klein C, Sleeman J, et al. Dermal fibroblasts induce maturation of dendritic cells. J Immunol. 2007;178:4966–4974.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang B, Wang F, et al. CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol. 2012;50:150–159.
   PubMed Web of Science ®Google Scholar
• Brown PM, Isaacs JD. Rheumatoid arthritis: an evolutionary force in biologics. Curr Pharm Des. 2015;21:2170–2178.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Paolino S, Pizzorni C, et al. Effects of combined treatments with CTLA4-IG (Abatacept), dexamethasone and methotrexate on cultured human macrophages. Clin. Exp. Rheumatol. 2016. (in press).
   Google Scholar